CM
IOVA icon

Crestline Management’s Iovance Biotherapeutics IOVA Stock Holding History

Crestline Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-93,346
Closed -$1.58M – 260
2018
Q1 		$1.58M Buy
+93,346
New +$1.41M 0.2% 102
2017
Q3 		– Sell
-43,254
Closed -$318K – 153
2017
Q2 		$318K Buy
+43,254
New +$275K 0.04% 120

Other funds holding IOVA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management's IOVA Position: Q2 2018 in Review

Crestline Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2018, closing a stake of 93,346 shares — an estimated $1.58M sold.

Crestline Management first reported a position in IOVA in Q2 2017 and held it in 2 quarters. The position peaked at $1.58M in Q1 2018. 126 funds tracked by Wall St. Rank hold IOVA as of Q2 2018.

  • Crestline Management reported no remaining Iovance Biotherapeutics position as of Q2 2018 after selling out during the quarter.
  • Crestline Management sold 93,346 Iovance Biotherapeutics shares in Q2 2018, an estimated $1.58M.
  • Crestline Management first reported a position in Iovance Biotherapeutics in Q2 2017 and held it in 2 quarters.
  • Crestline Management's Iovance Biotherapeutics position peaked at $1.58M in Q1 2018.
  • 126 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2018.

Based on Crestline Management's 13F filing for Q2 2018, filed 14 Aug 2018.